10:42:17 EDT Sun 23 Jun 2024
Enter Symbol
or Name
USA
CA



E:CYBN - CYBIN INC. - http://www.cybin.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CYBN - E  1.50.32·0.39516.00.35-0.01-2.81,209.73896780.36  0.365  0.3450.98  0.3116:18:22Jun 1915 min RT 2¢
NEO exchange - E1.50.32·0.39516.00.35-0.01-2.8847.12813360.36  0.365  0.3450.98  0.3116:18:2215 min
Omega - O 0.35-0.01-2.871.5181000.355  0.36  0.3515:59:3015 min
Chi-X - X 0.355-0.005-1.490.030340.355  0.36  0.3515:59:3015 min
CX2 - H 0.35-0.01-2.882.524750.36  0.36  0.34515:58:4915 min
CXD - D 0.35-0.01-2.8108.334730.355  0.355  0.3510:31:5215 min
TriAct - M 0.3610.3260    15 min

Recent Trades - Last 10 of 678
Time ETExPriceChangeVolumeBuyerSellerMarkers
16:18:22E0.35-0.010301 NEO Buy301 NEO BuyZ
15:59:30X0.355-0.00550079 CIBC39 Merrill LynchK
15:59:30O0.35-0.015002 RBC1 AnonymousK
15:59:30M0.355-0.00550079 CIBC1 Anonymous
15:59:30E0.35-0.011,00014 Virtu ITG1 AnonymousK
15:58:49X0.35-0.011,50079 CIBC1 AnonymousK
15:58:49X0.35-0.0150079 CIBC1 AnonymousK
15:58:49X0.35-0.014,50079 CIBC1 AnonymousK
15:58:49H0.35-0.011,0002 RBC1 AnonymousK
15:58:49H0.35-0.011,00079 CIBC1 AnonymousK

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2024-06-19 07:30C:CYBN0.365News ReleaseCybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
2024-06-11 10:54C:CYBN0.385News ReleaseCybin appoints Mahableshwarkar SVP, clinic development
2024-05-30 14:26C:CYBN0.465News ReleaseNuminus to host Cybin trial on CYB003 at Cedar Clinical
2024-05-06 14:09C:CYBN0.485News ReleaseCybin reviews recent CYB003 activities
2024-04-18 13:00C:CYBN0.51News ReleaseCybin publishes CYB210010 research manuscript
2024-04-16 12:27C:CYBN0.51News ReleaseCybin receives depressive disorder therapy patent
2024-04-08 07:12C:CYBN0.55In the NewsGlobe says MindMed, Cybin get nod from U.S. FDA
2024-03-19 12:42C:CYBN0.61News ReleaseCybin closes $150-million (U.S.) private placement
2024-03-15 09:12C:CYBN0.61News ReleaseCybin begins phase 2 CYB004 study for GAD treatment
2024-03-14 11:30C:CYBN0.58News ReleaseCybin talks CYB003 phase 2 FDA meeting, phase 3 design
2024-03-13 09:16C:CYBN0.58News ReleaseCybin arranges $150-million (U.S.) private placement
2024-03-13 08:59C:CYBN0.57News ReleaseCybin's CYB003 receives FDA breakthrough designation
2024-03-12 23:17C:CYBN0.58News ReleaseCybin to host call March 13 for CYB003 update
2024-02-14 12:40C:CYBN0.475News ReleaseCybin has cash of $39-million at Dec. 31
2024-02-14 07:40C:CYBN0.475SEDAR Interim MD & ASEDAR Interim MD & A
2024-02-14 07:34C:CYBN0.475SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-02-07 11:55C:CYBN0.395News ReleaseCybin receives two patents in Japan for DMT program
2024-01-23 09:05C:CYBN0.485News ReleaseCybin receives FDA OK to begin phase 2a CYB004 study
2024-01-08 11:46C:CYBN0.54News ReleaseCybin says CYB004, SPL028 well tolerated in phase 1
2024-01-04 10:54C:CYBN0.52News ReleaseCybin outlines phase 2 CYB003 results in MDD